Nanobiotix: Voting Rights and Shares Capital of the Company

Rhea-AI Summary

Nanobiotix reported updated information regarding its outstanding shares and voting rights as of September 30, 2022. Currently, there are 34,875,872 shares outstanding, with a total of 36,277,898 theoretical voting rights and 36,261,825 exercisable voting rights. This data is crucial for ensuring transparency for shareholders and aligns with the French regulatory requirements.

Positive

• Transparency in share and voting rights data enhances trust among investors.
• Total voting rights provide clarity on shareholder influence and governance.

Negative

• None.

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS--(BUSINESS WIRE)-- Regulatory News:

Nanobiotix (Paris:NANO) (NASDAQ:NBTX):

Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, theoretical (1)	Total voting rights, exercisable (2)
September 30, 2022	34,875,872	36,277,898	36,261,825

⁽¹⁾ The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

⁽²⁾ The total number of exercisable at a Shareholders’ Meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

***

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221010005340/en/

Nanobiotix

Nanobiotix Communications

Brandon Owens

VP, Communications

+1 (617) 852-4835

contact@nanobiotix.com

Nanobiotix Investor Relations

Kate McNeil

SVP, Investor Relations

+1 (609) 678-7388

investors@nanobiotix.com

Media Relations

France – Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51

plgermain@ulysse-communication.com

LifeSci Advisors

Ligia Vela-Reid

+44 (0) 7413825310

lvela-reid@lifesciadvisors.com

Source: Nanobiotix

FAQ

What is the total number of shares outstanding for NBTX as of September 30, 2022?

As of September 30, 2022, the total number of shares outstanding for NBTX is 34,875,872.

How many theoretical voting rights does NBTX have as of September 30, 2022?

NBTX has a total of 36,277,898 theoretical voting rights as of September 30, 2022.

What are the exercisable voting rights for NBTX on September 30, 2022?

The exercisable voting rights for NBTX on September 30, 2022, amount to 36,261,825.

What is the significance of the voting rights data for NBTX shareholders?

The voting rights data is important for shareholders as it reflects their ability to influence company decisions and governance.

Where can I find more information about Nanobiotix?

More information about Nanobiotix can be found on their official website at www.nanobiotix.com.